Meiji Holdings Co., Ltd. (MEJHY)

OTCMKTS · Delayed Price · Currency is USD
11.74
0.00 (0.00%)
May 11, 2026, 9:30 AM EST
Market Cap6.18B -2.5%
Revenue (ttm)7.41B +1.2%
Net Income293.36M -6.8%
EPS1.08 -5.4%
Shares Outn/a
PE Ratio21.06
Forward PEn/a
Dividend0.68 (5.81%)
Ex-Dividend DateMar 30, 2026
Volume200
Average Volume448
Open11.74
Previous Close11.74
Day's Range11.74 - 11.74
52-Week Range9.12 - 14.81
Beta0.11
RSI49.70
Earnings DateMay 14, 2026

About Meiji Holdings

Meiji Holdings Co., Ltd., through its subsidiaries, engages in the manufacture and sale of dairy products, confectionery food products and pharmaceuticals in Japan and internationally. The company operates through two segments, Food and Pharmaceuticals. The Food segment provides yogurt, milk, beverages, cheese, butter, margarine, cream, ice cream, prepared food, chocolate, gummy candy, sports nutrition, infant milk, liquid food, beauty products, feed, sugar, and corn sweeteners. The Pharmaceutical segment offers drugs for infectious and central... [Read more]

Founded 1916
Employees 17,231
Stock Exchange OTCMKTS
Ticker Symbol MEJHY

Financial Performance

In fiscal year 2025, Meiji Holdings's revenue was 1.15 trillion, an increase of 4.39% compared to the previous year's 1.11 trillion. Earnings were 50.80 billion, an increase of 0.25%.

Financial numbers in JPY Financial Statements

News

Meiji Holdings Earnings Call Transcript: Q2 2026

First half operating profit exceeded plan despite a slight sales shortfall, driven by strong pharmaceuticals and effective price increases. Full-year sales guidance was revised down, but profit targets remain, with ongoing structural reforms and new product launches supporting growth.

6 months ago - Transcripts

Meiji Holdings Earnings Call Transcript: Q2 2025

First-half net sales rose 4.2% year-on-year, with operating profit flat and profit attributable to owners down 3.8% due to lower extraordinary gains. Food segment faced cost pressures but expects recovery via price hikes, while pharma segment saw strong first half but faces lower second-half profit from reduced COVID vaccine demand.

1 year ago - Transcripts